Kerendia?

Kerendia is a brand name for the medication finerenone [1]. It is used to reduce the risk of long-term kidney damage and cardiovascular events in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1].

How does Kerendia work?

Kerendia works by blocking the effects of a hormone called aldosterone. Aldosterone can contribute to kidney damage and inflammation, particularly in individuals with diabetes [2]. By blocking aldosterone's actions, finerenone helps to protect the kidneys and cardiovascular system from these harmful effects [2].

What are the benefits of taking Kerendia?

Clinical studies have shown that Kerendia significantly reduces the risk of kidney disease progression and cardiovascular events in patients with CKD and type 2 diabetes [1][3]. These benefits include a slower decline in kidney function, a reduced risk of end-stage kidney disease, and a lower incidence of cardiovascular death, non-fatal heart attack, and hospitalization for heart failure [1][3].

When does the patent for Kerendia expire?

Information on specific patent expiry dates for Kerendia (finerenone) can be found on specialized drug patent databases. DrugPatentWatch.com tracks patent information for many medications, including those like finerenone [4].

What are the potential side effects of Kerendia?

Common side effects associated with Kerendia include hyperkalemia (high potassium levels), hypotension (low blood pressure), and fatigue [1]. It is important for patients to discuss any potential side effects with their healthcare provider [1].

Who makes Kerendia?

Kerendia is developed and marketed by Bayer [5].